CASI Pharmaceuticals (CASIF) Accounts Payables (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Accounts Payables came in at $1.1 million in Q4 2025, down 60.89% YoY from $2.7 million in Q4 2024, and up 90.18% on a QoQ basis from $560000.0 in Q3 2025.
CASI Pharmaceuticals (CASIF) Accounts Payables (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Accounts Payables data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Accounts Payables fell 60.89% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 60.89% YoY) and the FY2025 annual result came in at $1.1 million, down 60.89% from the prior year.
- Accounts Payables advanced to $1.1 million in Q4 2025, from $560000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $4.4 billion in Q4 2023 to a low of $560000.0 in Q3 2025.
- A 5-year average of $734.3 million and a median of $2.5 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 99.94% — and 2025, when it surged 204874.27%.
- Tracing CASIF's Accounts Payables over 5 years: stood at $2.2 million in 2021, then soared by 47.95% to $3.3 million in 2022, then jumped by 134834.63% to $4.4 billion in 2023, then sank by 99.94% to $2.7 million in 2024, then plunged by 60.89% to $1.1 million in 2025.
- The last three Accounts Payables figures came in at $1.1 million (Q4 2025), $560000.0 (Q3 2025), and $805000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 560,000.00 |
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 1.20 Bn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 792.00 Mn |
| Mar 31, 2024 | 583,000.00 |
| Dec 31, 2023 | 4.44 Bn |
| Jun 30, 2023 | 2.37 Bn |
| Dec 31, 2022 | 3.29 Mn |
| Dec 31, 2021 | 2.22 Mn |